Noribogaine effects on wakefulness and sleep

Summary

Noribogaine, a metabolite of the psychedelic ibogaine, promotes wakefulness while reducing slow-wave sleep and blocking REM sleep in rats. This study shows that noribogaine significantly alters sleep-wake architecture, similar to ibogaine, suggesting that serotonin reuptake inhibition may play a role in these effects. The findings highlight the potential therapeutic implications of noribogaine's distinct pharmacological profile.

Study at a glance

Abstract

Abstract Ibogaine is a potent atypical psychedelic that has gained considerable attention due to its antiaddictive and antidepressant properties in preclinical and clinical studies. Previous research from our group showed that ibogaine suppresses sleep and produces an altered wakefulness state which resembles natural REM sleep. However, after systemic administration, ibogaine is rapidly metabolized to noribogaine, which also shows antiaddictive effects and a distinct pharmacological profile, making this drug a promising therapeutic candidate. Therefore, whether the sleep/wake alterations depend on ibogaine or its principal metabolite noribogaine remains unknown. To answer this question, we conducted polysomnographic recordings in rats following the administration of pure noribogaine. Our results show that noribogaine promotes wakefulness while reducing slow-wave sleep and blocking REM sleep. Thus, like ibogaine, noribogaine significantly alters the sleep-wake architecture, highlighting the possible role of serotonin reuptake inhibition as a likely candidate underlying the wake-promoting and REM sleep-suppressing effects.

Tags